Natural products' antiangiogenic roles in gynecological cancer

Shangmei Jia1, Ling Li1,2, Chenghao Yu1

  • 1State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

PubMed

Insights

This review identifies 63 natural products with anti-angiogenic activity against gynecological cancer. These compounds offer potential for targeted vascular therapies and new drug development in women

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products Research

Background:

  • Gynecological cancers represent a major health concern for women globally.
  • Angiogenesis, the formation of new blood vessels, is a critical process in the growth, invasion, and metastasis of gynecological tumors.
  • Targeting angiogenesis using natural products is a promising therapeutic strategy for gynecological cancer.

Purpose of the Study:

  • To systematically review and identify natural products exhibiting anti-angiogenic properties against gynecological cancers.
  • To explore the potential of these natural products in targeted vascular therapy for gynecological malignancies.
  • To provide a theoretical foundation for the development of novel anti-cancer drugs derived from natural sources.

Main Methods:

  • Comprehensive literature searches were conducted in major scientific databases (PubMed, Embase, Web of Science, Science Direct, CNKI) up to May 2023.
  • Studies focusing on natural products with anti-angiogenic effects on gynecological tumors were included.
  • Identified natural products were analyzed for their mechanisms of action and therapeutic potential.

Main Results:

  • A total of 63 natural products demonstrating anti-angiogenic activity against gynecological cancer were identified.
  • These natural products modulate angiogenesis, thereby impacting tumor growth, invasion, and metastasis.
  • The findings highlight the role of these compounds in influencing the tumor microenvironment.

Conclusions:

  • Natural products with anti-angiogenic effects represent a significant resource for developing novel treatments for gynecological cancers.
  • Targeting tumor angiogenesis with these compounds offers a promising avenue for developing targeted vascular therapies.
  • This review lays the groundwork for future research into natural product-based drug development for gynecological malignancies.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521